SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

EyePoint Pharmaceuticals, Inc. – ‘10-K’ for 6/30/17 – ‘EX-3.2’

On:  Wednesday, 9/13/17, at 4:47pm ET   ·   For:  6/30/17   ·   Accession #:  1193125-17-283875   ·   File #:  0-51122

Previous ‘10-K’:  ‘10-K’ on 9/13/16 for 6/30/16   ·   Next:  ‘10-K/A’ on 10/30/17 for 6/30/17   ·   Latest:  ‘10-K’ on 3/8/24 for 12/31/23   ·   31 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/13/17  EyePoint Pharmaceuticals, Inc.    10-K        6/30/17   99:6.4M                                   Donnelley … Solutions/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.01M 
 2: EX-3.2      Articles of Incorporation/Organization or Bylaws    HTML     30K 
 3: EX-10.10    Material Contract                                   HTML     32K 
 4: EX-10.18    Material Contract                                   HTML     57K 
 5: EX-10.19    Material Contract                                   HTML     51K 
 6: EX-10.23    Material Contract                                   HTML    258K 
 7: EX-10.25    Material Contract                                   HTML     34K 
 8: EX-21.1     Subsidiaries List                                   HTML     26K 
 9: EX-23.1     Consent of Experts or Counsel                       HTML     27K 
10: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
11: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
12: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
13: EX-32.2     Certification -- §906 - SOA'02                      HTML     28K 
20: R1          Document and Entity Information                     HTML     57K 
21: R2          Consolidated Balance Sheets                         HTML    106K 
22: R3          Consolidated Balance Sheets (Parenthetical)         HTML     46K 
23: R4          Consolidated Statements of Comprehensive (Loss)     HTML     88K 
                Income                                                           
24: R5          Consolidated Statements of Stockholders' Equity     HTML     71K 
25: R6          Consolidated Statements of Cash Flows               HTML    104K 
26: R7          Operations                                          HTML     40K 
27: R8          Significant Accounting Policies                     HTML     98K 
28: R9          License and Collaboration Agreements                HTML     51K 
29: R10         Intangible Assets                                   HTML     45K 
30: R11         Marketable Securities                               HTML     38K 
31: R12         Property and Equipment, Net                         HTML     36K 
32: R13         Fair Value Measurements                             HTML     55K 
33: R14         Accrued Expenses                                    HTML     35K 
34: R15         Restructuring                                       HTML     42K 
35: R16         Stockholders' Equity                                HTML     45K 
36: R17         Stock-Based Compensation                            HTML     84K 
37: R18         Retirement Plans                                    HTML     31K 
38: R19         Income Taxes                                        HTML     79K 
39: R20         Commitments and Contingencies                       HTML     44K 
40: R21         Segment and Geographic Area Information             HTML     38K 
41: R22         Quarterly Financial Data (Unaudited)                HTML     54K 
42: R23         Significant Accounting Policies (Policies)          HTML    136K 
43: R24         Significant Accounting Policies (Tables)            HTML     45K 
44: R25         Intangible Assets (Tables)                          HTML     47K 
45: R26         Marketable Securities (Tables)                      HTML     37K 
46: R27         Property and Equipment, Net (Tables)                HTML     35K 
47: R28         Fair Value Measurements (Tables)                    HTML     45K 
48: R29         Accrued Expenses (Tables)                           HTML     34K 
49: R30         Restructuring (Tables)                              HTML     37K 
50: R31         Stockholders' Equity (Tables)                       HTML     39K 
51: R32         Stock-Based Compensation (Tables)                   HTML     71K 
52: R33         Income Taxes (Tables)                               HTML     74K 
53: R34         Commitments and Contingencies (Tables)              HTML     34K 
54: R35         Segment and Geographic Area Information (Tables)    HTML     38K 
55: R36         Quarterly Financial Data (Unaudited) (Tables)       HTML     54K 
56: R37         Operations - Additional Information (Detail)        HTML     37K 
57: R38         Significant Accounting Policies - Additional        HTML    115K 
                Information (Detail)                                             
58: R39         Significant Accounting Policies - Schedule that     HTML     40K 
                Reconciles the Number of Shares Used to Compute                  
                Basic and Diluted Net (Loss) Income per Share                    
                (Detail)                                                         
59: R40         Significant Accounting Policies - Potentially       HTML     42K 
                Dilutive Securities Excluded from Computation of                 
                Diluted Weighted-Average Shares (Detail)                         
60: R41         License and Collaboration Agreements - Additional   HTML    127K 
                Information (Detail)                                             
61: R42         Intangible Assets - Reconciliation of Intangible    HTML     43K 
                Assets (Detail)                                                  
62: R43         Intangible Assets - Schedule of Net Book Value of   HTML     37K 
                Intangible Assets (Detail)                                       
63: R44         Intangible Assets - Additional Information          HTML     33K 
                (Detail)                                                         
64: R45         Marketable Securities - Additional Information      HTML     36K 
                (Detail)                                                         
65: R46         Marketable Securities - Schedule of Amortized       HTML     41K 
                Cost, Unrealized Loss and Fair Value of                          
                Available-for-Sale Marketable Securities (Detail)                
66: R47         Property and Equipment, Net - Schedule of Property  HTML     41K 
                and Equipment (Detail)                                           
67: R48         Property and Equipment, Net - Additional            HTML     31K 
                Information (Detail)                                             
68: R49         Fair Value Measurements - Assets Carried at Fair    HTML     53K 
                Value Measured on Recurring Basis (Detail)                       
69: R50         Accrued Expenses - Schedule of Accrued Expenses     HTML     41K 
                (Detail)                                                         
70: R51         Accrued Expenses - Additional Information (Detail)  HTML     34K 
71: R52         Restructuring - Additional Information (Detail)     HTML     50K 
72: R53         Restructuring - Summary of Reconciliation of        HTML     45K 
                Restructuring Costs (Detail)                                     
73: R54         Stockholders' Equity - Additional Information       HTML     54K 
                (Detail)                                                         
74: R55         Stockholders' Equity - Summary of Reconciliation    HTML     37K 
                of Warrants to Purchase Common Stock (Detail)                    
75: R56         Stock-Based Compensation - 2016 Long Term           HTML     76K 
                Incentive Plan - Additional Information (Detail)                 
76: R57         Stock-Based Compensation - Key Assumptions Used to  HTML     39K 
                Apply Option Pricing Model For Options Granted                   
                (2016 Long Term Incentive Plan) (Detail)                         
77: R58         Stock-Based Compensation - 2008 Incentive Plan -    HTML     57K 
                Additional Information (Detail)                                  
78: R59         Stock-Based Compensation - Key Assumptions Used to  HTML     49K 
                Apply Option Pricing Model For Options Granted                   
                (2008 Incentive Plan) (Detail)                                   
79: R60         Stock-Based Compensation - Summary of Information   HTML     39K 
                about Stock Options (Detail)                                     
80: R61         Stock-Based Compensation - Stock Option Activity    HTML     79K 
                Under Plan (Detail)                                              
81: R62         Stock-Based Compensation - Inducement Option Grant  HTML     53K 
                - Additional Information (Detail)                                
82: R63         Stock-Based Compensation - Restricted Stock Units   HTML     38K 
                - Additional Information (Detail)                                
83: R64         Stock-Based Compensation - Key Assumptions Used to  HTML     46K 
                Estimate Fair Value of Market-based RSU (Detail)                 
84: R65         Stock-Based Compensation - Compensation Expense     HTML     37K 
                from Stock-Based Payment Awards (Detail)                         
85: R66         Stock-Based Compensation - Stock-Based              HTML     41K 
                Compensation Expense - Additional Information                    
                (Detail)                                                         
86: R67         Retirement Plans - Additional Information (Detail)  HTML     32K 
87: R68         Income Taxes - Components of Income Tax (Benefit)   HTML     42K 
                Expense (Detail)                                                 
88: R69         Income Taxes - Additional Information (Detail)      HTML     89K 
89: R70         Income Taxes - Components of (Loss) Income Before   HTML     36K 
                Income Taxes (Detail)                                            
90: R71         Income Taxes - Difference Between Expected Income   HTML     52K 
                Tax (Benefit) Expense and Actual Income Tax                      
                (Benefit) Expense (Detail)                                       
91: R72         Income Taxes - Significant Components of Deferred   HTML     56K 
                Income Taxes (Detail)                                            
92: R73         Commitments and Contingencies - Additional          HTML     78K 
                Information (Detail)                                             
93: R74         Commitments and Contingencies - Future Minimum      HTML     44K 
                Lease Payments Under Non-Cancellable Operating                   
                Leases (Detail)                                                  
94: R75         Segment and Geographic Area Information - Summary   HTML     44K 
                of Company's Revenues and Long-Lived Assets, Net,                
                by Geographic Area (Detail)                                      
95: R76         Quarterly Financial Data - Summary of Quarterly     HTML     44K 
                Results of Operations (Detail)                                   
96: R77         Quarterly Financial Data - Summary of Quarterly     HTML     31K 
                Results of Operations (Parenthetical) (Detail)                   
98: XML         IDEA XML File -- Filing Summary                      XML    172K 
97: EXCEL       IDEA Workbook of Financial Reports                  XLSX     96K 
14: EX-101.INS  XBRL Instance -- psdv-20170630                       XML   1.47M 
16: EX-101.CAL  XBRL Calculations -- psdv-20170630_cal               XML    217K 
17: EX-101.DEF  XBRL Definitions -- psdv-20170630_def                XML    643K 
18: EX-101.LAB  XBRL Labels -- psdv-20170630_lab                     XML   1.32M 
19: EX-101.PRE  XBRL Presentations -- psdv-20170630_pre              XML   1.00M 
15: EX-101.SCH  XBRL Schema -- psdv-20170630                         XSD    204K 
99: ZIP         XBRL Zipped Folder -- 0001193125-17-283875-xbrl      Zip    173K 


‘EX-3.2’   —   Articles of Incorporation/Organization or Bylaws


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-3.2  

Exhibit 3.2

CERTIFICATE OF AMENDMENT OF THE

CERTIFICATE OF INCORPORATION

OF

PSIVIDA CORP.

pSivida Corp. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), for the purpose of amending its Certificate of Incorporation, as amended (the Certificate of Incorporation), in accordance with the DGCL, does hereby make and execute this Certificate of Amendment to the Certificate of Incorporation, and does hereby certify that:

1. The Board of Directors of the Corporation (the “Board”), acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions amending its Certificate of Incorporation, so that effective upon the effective time of this Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware, Article 4 of the Certificate of Incorporation is hereby amended by striking out Article 4 thereof and by substituting in lieu of said Article the following new Article 4:

“4. The corporation shall have two classes of stock, Common Stock, US$.001 par value per share, and Preferred Stock, US$.001 par value per share. The total number of shares that the corporation shall have authority to issue is 120,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. Subject to the limitations prescribed by law and the provisions of this certificate of incorporation, the board of directors of the corporation is authorized to issue the Preferred Stock from time to time in one or more series, each of such series to have such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights, and such qualifications, limitations or restrictions thereof, as shall be determined by the board of directors in a resolution or resolutions providing for the issue of such Preferred Stock. Subject to the powers, preferences and rights of any Preferred Stock, including any series thereof, having any preference or priority over, or rights superior to, the Common Stock and except as otherwise provided by law, the holders of the Common Stock shall have and possess all powers and voting and other rights pertaining to the stock of this corporation and each share of Common Stock shall be entitled to one vote.”

2. Thereafter, pursuant to a resolution of the Board, a special meeting of the stockholders of the Corporation was duly called and held upon notice in accordance with Section 222 of the DGCL at which meeting the necessary number of shares as required by statute were voted in favor of the foregoing amendment.

3. The foregoing amendment has been duly adopted in accordance with the provisions of Section 242 of the DGCL by the vote of a majority of outstanding stock of the Corporation entitled to vote thereon.

4. This Certificate of Amendment of the Certificate of Incorporation shall be effective upon its filing with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, I have signed this Certificate this 27th day of June, 2017.

 

/s/ Nancy S. Lurker

Nancy S. Lurker
President and Chief Executive Officer

31 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/09/24  EyePoint Pharmaceuticals, Inc.    10-Q        3/31/24   71:7.3M                                   Donnelley … Solutions/FA
 3/08/24  Alimera Sciences Inc.             10-K       12/31/23   95:16M
 3/08/24  EyePoint Pharmaceuticals, Inc.    10-K       12/31/23  100:11M                                    Donnelley … Solutions/FA
11/03/23  EyePoint Pharmaceuticals, Inc.    10-Q        9/30/23   79:9M                                     Donnelley … Solutions/FA
10/20/23  EyePoint Pharmaceuticals, Inc.    S-3                    5:779K                                   Donnelley … Solutions/FA
10/20/23  EyePoint Pharmaceuticals, Inc.    S-8        10/20/23    4:118K                                   Donnelley … Solutions/FA
 8/04/23  EyePoint Pharmaceuticals, Inc.    10-Q        6/30/23   80:9.9M                                   Donnelley … Solutions/FA
 5/04/23  EyePoint Pharmaceuticals, Inc.    10-Q        3/31/23   80:9.4M                                   Donnelley … Solutions/FA
 3/31/23  Alimera Sciences Inc.             10-K       12/31/22   99:15M
 3/10/23  EyePoint Pharmaceuticals, Inc.    10-K       12/31/22  115:17M                                    Donnelley … Solutions/FA
 1/09/23  EyePoint Pharmaceuticals, Inc.    S-8         1/09/23    4:124K                                   Donnelley … Solutions/FA
11/04/22  EyePoint Pharmaceuticals, Inc.    10-Q        9/30/22   80:11M                                    Donnelley … Solutions/FA
 8/05/22  EyePoint Pharmaceuticals, Inc.    10-Q        6/30/22   85:11M                                    Donnelley … Solutions/FA
 5/06/22  EyePoint Pharmaceuticals, Inc.    10-Q        3/31/22   80:9.2M                                   ActiveDisclosure/FA
 4/29/22  Alimera Sciences Inc.             10-K/A     12/31/21   12:1.5M
 3/23/22  Alimera Sciences Inc.             10-K       12/31/21   98:9.5M
 3/14/22  EyePoint Pharmaceuticals, Inc.    10-K       12/31/21  103:15M                                    ActiveDisclosure/FA
11/05/21  EyePoint Pharmaceuticals, Inc.    10-Q        9/30/21   78:9.4M                                   ActiveDisclosure/FA
 8/06/21  EyePoint Pharmaceuticals, Inc.    10-Q        6/30/21   79:9.2M                                   ActiveDisclosure/FA
 8/06/21  EyePoint Pharmaceuticals, Inc.    S-3                    5:2.3M                                   Donnelley … Solutions/FA
 8/06/21  EyePoint Pharmaceuticals, Inc.    S-8         8/06/21    3:73K                                    Donnelley … Solutions/FA
 5/05/21  EyePoint Pharmaceuticals, Inc.    10-Q        3/31/21   81:8.9M                                   ActiveDisclosure/FA
 5/05/21  EyePoint Pharmaceuticals, Inc.    S-3/A                  2:226K                                   Donnelley … Solutions/FA
 5/04/21  EyePoint Pharmaceuticals, Inc.    10-K/A     12/31/20   14:826K                                   Donnelley … Solutions/FA
 3/12/21  EyePoint Pharmaceuticals, Inc.    10-K       12/31/20  108:13M                                    ActiveDisclosure/FA
 3/05/21  Alimera Sciences Inc.             10-K       12/31/20   95:14M
 2/12/21  EyePoint Pharmaceuticals, Inc.    S-3                    3:260K                                   Donnelley … Solutions/FA
 1/15/21  EyePoint Pharmaceuticals, Inc.    S-3                    4:662K                                   Donnelley … Solutions/FA
11/06/20  EyePoint Pharmaceuticals, Inc.    10-Q        9/30/20   85:9.8M                                   ActiveDisclosure/FA
11/06/20  EyePoint Pharmaceuticals, Inc.    S-8        11/06/20    3:88K                                    Donnelley … Solutions/FA
 8/05/20  EyePoint Pharmaceuticals, Inc.    10-Q        6/30/20   82:9.5M                                   ActiveDisclosure/FA
Top
Filing Submission 0001193125-17-283875   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 8:01:21.2pm ET